TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also advanced TS-102 into IND-enabling activities. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors. It has collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. Show more
Location: 830 Winter Street, Waltham, MA, 02451, United States | Website: https://www.tscan.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
102.4M
52 Wk Range
$1.02 - $7.89
Previous Close
$1.84
Open
$1.84
Volume
228,721
Day Range
$1.76 - $1.86
Enterprise Value
-72.6M
Cash
251.7M
Avg Qtr Burn
-29.79M
Insider Ownership
0.23%
Institutional Own.
88.08%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Phase 1 Data readout | ||
TSC-100 & TSC-101 Details Acute Myeloid Leukemia (AML), Acute lymphoblastic leukemia (ALL), Myelodysplastic syndrome (MDS) | Phase 1 Data readout |